A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China
Background and objective: Treatment landscape in advanced prostate cancer (PC) is evolving. There is limited understanding of the factors influencing decision-making for genetic/genomic testing and the barriers to recommending testing and treatment in international real-world clinical practice follo...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | European Urology Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666168324006153 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533272070291456 |
|---|---|
| author | Christian Gratzke Himani Aggarwal Jeri Kim Holly Chaignaud Sabine Oskar |
| author_facet | Christian Gratzke Himani Aggarwal Jeri Kim Holly Chaignaud Sabine Oskar |
| author_sort | Christian Gratzke |
| collection | DOAJ |
| description | Background and objective: Treatment landscape in advanced prostate cancer (PC) is evolving. There is limited understanding of the factors influencing decision-making for genetic/genomic testing and the barriers to recommending testing and treatment in international real-world clinical practice following the approval of poly-adenosine diphosphate-ribose polymerase inhibitors (PARPi) for metastatic castration-resistant PC (mCRPC). This work aims to assess genetic/genomic testing patterns and methods, including for homologous recombination repair mutation (HRRm), and treatment decisions among physicians caring for patients with PC across the USA, Europe, and Asia. Methods: A cross-sectional online survey of physicians treating patients with advanced PC was administered in the USA, France, Germany, Italy, Spain, UK, Japan, and China. Physicians were recruited (from August to December 2022) via clinical panels and provided informed consent. Survey questions covered factors influencing HRRm testing and treatment decision-making. Key findings and limitations: Physicians reported that 50% of patients with mCRPC are recommended for HRRm testing, and among those recommended for testing, 60% are recommended for BRCA1/2 mutation testing and 65% go on to receive HRRm testing. Overall proportions of patients recommended for testing increased following PARPi approval (from 20% to 50%) and following updated practice guidelines (from 25% to 50%). Perceived barriers to the use of genetic/genomic testing included patient refusal, lack of insurance/reimbursement, and lack of availability of adequate tissue for testing. Conclusions and clinical implications: Overall, testing rates increased following PARPi approval and updated clinical practice guidelines; yet, there was a wide variation in the proportions of patients with mCRPC recommended for testing, and perceived barriers to testing remain, suggesting unmet needs for patients and physicians. Patient summary: We surveyed physicians globally about their experience in treating patients with advanced prostate cancer and genetic testing. Physicians reported that half of patients are recommended for genetic testing, which varied across countries. We conclude that barriers to testing remain for patients and physicians. |
| format | Article |
| id | doaj-art-e9ef3f70a28544ce84d151c4707e3f7e |
| institution | Kabale University |
| issn | 2666-1683 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Urology Open Science |
| spelling | doaj-art-e9ef3f70a28544ce84d151c4707e3f7e2025-01-17T04:52:18ZengElsevierEuropean Urology Open Science2666-16832025-01-0171148155A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and ChinaChristian Gratzke0Himani Aggarwal1Jeri Kim2Holly Chaignaud3Sabine Oskar4Department of Urology, University Hospital Freiburg, Freiburg, Germany; Corresponding author. Department of Urology, University Hospital Freiburg, Hugstetterstr. 55, Freiburg 79106, Germany. Tel. +49 177-309-7411; Fax: +49 761-270-19310.Merck & Co. Inc, Rahway, NJ, USAMerck & Co. Inc, Rahway, NJ, USAOPEN Health, London, UKMerck & Co. Inc, Rahway, NJ, USABackground and objective: Treatment landscape in advanced prostate cancer (PC) is evolving. There is limited understanding of the factors influencing decision-making for genetic/genomic testing and the barriers to recommending testing and treatment in international real-world clinical practice following the approval of poly-adenosine diphosphate-ribose polymerase inhibitors (PARPi) for metastatic castration-resistant PC (mCRPC). This work aims to assess genetic/genomic testing patterns and methods, including for homologous recombination repair mutation (HRRm), and treatment decisions among physicians caring for patients with PC across the USA, Europe, and Asia. Methods: A cross-sectional online survey of physicians treating patients with advanced PC was administered in the USA, France, Germany, Italy, Spain, UK, Japan, and China. Physicians were recruited (from August to December 2022) via clinical panels and provided informed consent. Survey questions covered factors influencing HRRm testing and treatment decision-making. Key findings and limitations: Physicians reported that 50% of patients with mCRPC are recommended for HRRm testing, and among those recommended for testing, 60% are recommended for BRCA1/2 mutation testing and 65% go on to receive HRRm testing. Overall proportions of patients recommended for testing increased following PARPi approval (from 20% to 50%) and following updated practice guidelines (from 25% to 50%). Perceived barriers to the use of genetic/genomic testing included patient refusal, lack of insurance/reimbursement, and lack of availability of adequate tissue for testing. Conclusions and clinical implications: Overall, testing rates increased following PARPi approval and updated clinical practice guidelines; yet, there was a wide variation in the proportions of patients with mCRPC recommended for testing, and perceived barriers to testing remain, suggesting unmet needs for patients and physicians. Patient summary: We surveyed physicians globally about their experience in treating patients with advanced prostate cancer and genetic testing. Physicians reported that half of patients are recommended for genetic testing, which varied across countries. We conclude that barriers to testing remain for patients and physicians.http://www.sciencedirect.com/science/article/pii/S2666168324006153Genetic testingHomologous recombination repair mutationMetastatic castration-resistant prostate cancerPoly-adenosine diphosphate-ribose polymerase inhibitorsReal-world data |
| spellingShingle | Christian Gratzke Himani Aggarwal Jeri Kim Holly Chaignaud Sabine Oskar A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China European Urology Open Science Genetic testing Homologous recombination repair mutation Metastatic castration-resistant prostate cancer Poly-adenosine diphosphate-ribose polymerase inhibitors Real-world data |
| title | A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China |
| title_full | A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China |
| title_fullStr | A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China |
| title_full_unstemmed | A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China |
| title_short | A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China |
| title_sort | cross sectional survey of physicians to understand biomarker testing and treatment patterns in patients with prostate cancer in the usa eu5 japan and china |
| topic | Genetic testing Homologous recombination repair mutation Metastatic castration-resistant prostate cancer Poly-adenosine diphosphate-ribose polymerase inhibitors Real-world data |
| url | http://www.sciencedirect.com/science/article/pii/S2666168324006153 |
| work_keys_str_mv | AT christiangratzke acrosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT himaniaggarwal acrosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT jerikim acrosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT hollychaignaud acrosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT sabineoskar acrosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT christiangratzke crosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT himaniaggarwal crosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT jerikim crosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT hollychaignaud crosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina AT sabineoskar crosssectionalsurveyofphysicianstounderstandbiomarkertestingandtreatmentpatternsinpatientswithprostatecancerintheusaeu5japanandchina |